Two Pharma Firms in India Begin Phase IV Efficacy Trial for COVID-19 Drug, an Industrial Info Market Brief
Two Pharma Firms in India Begin Phase IV Efficacy Trial for COVID-19 Drug, an Industrial Info Market Brief
Attachment: India COVID drug 0920
India's Central Drugs Standard Control Organisation (CDSCO) recently granted approval to pharmaceutical majors Cipla Limited and Optimus Pharma Limited to conduct Phase IV trials for Favipiravir, the most sought-after medicine in the treatment of mild to moderate symptoms of COVID-19.
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- France Plans $55 Billion in Windfarms as Offshore Projects Gain Momentum
- Africa's Fertilizer Demand Sparks $5.8 Billion of Projects
- Poland's PGE Plans $7 Billion Renewable Energy Push
- Peru's Runoff Presidential Election Could Impact $45 Billion in Mining Proj...
- Industrial Construction Activity Up 37% So Far in 2021
Quick Links
- Home
- About Us
- Contact Us
- For Traders
Global Market Intelligence
- GMI Database Platform
- GMI Platform Tools
- Industry Coverage
- Analytics & Insights
- Advertising
